DK573182A - Fremgangsmaade til fremstilling af 2-(4-((4,4-dialkyl-2,6-piperidindion-1-yl)butyl)-1-piperasinyl)pyrimidiner - Google Patents

Fremgangsmaade til fremstilling af 2-(4-((4,4-dialkyl-2,6-piperidindion-1-yl)butyl)-1-piperasinyl)pyrimidiner Download PDF

Info

Publication number
DK573182A
DK573182A DK573182A DK573182A DK573182A DK 573182 A DK573182 A DK 573182A DK 573182 A DK573182 A DK 573182A DK 573182 A DK573182 A DK 573182A DK 573182 A DK573182 A DK 573182A
Authority
DK
Denmark
Prior art keywords
piperidindion
piperasinyl
pyrimidines
dialkyl
butyl
Prior art date
Application number
DK573182A
Other languages
English (en)
Other versions
DK162389B (da
DK162389C (da
Inventor
Davis L Temple
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of DK573182A publication Critical patent/DK573182A/da
Publication of DK162389B publication Critical patent/DK162389B/da
Application granted granted Critical
Publication of DK162389C publication Critical patent/DK162389C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK573182A 1981-12-28 1982-12-23 Analogifremgangsmaade til fremstilling af 2-oe4-oe(4,4-dialkyl-2,6-piperidindion-1-yl)butylaa-1-piperazinylaapyrimidiner DK162389C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/334,688 US4423049A (en) 1981-12-28 1981-12-28 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US33468881 1981-12-28

Publications (3)

Publication Number Publication Date
DK573182A true DK573182A (da) 1983-06-29
DK162389B DK162389B (da) 1991-10-21
DK162389C DK162389C (da) 1992-03-09

Family

ID=23308351

Family Applications (1)

Application Number Title Priority Date Filing Date
DK573182A DK162389C (da) 1981-12-28 1982-12-23 Analogifremgangsmaade til fremstilling af 2-oe4-oe(4,4-dialkyl-2,6-piperidindion-1-yl)butylaa-1-piperazinylaapyrimidiner

Country Status (26)

Country Link
US (1) US4423049A (da)
JP (2) JPS58118582A (da)
KR (1) KR870001045B1 (da)
AT (1) AT382373B (da)
AU (1) AU555797B2 (da)
BE (1) BE895504A (da)
CA (1) CA1244426A (da)
CH (1) CH656383A5 (da)
CY (1) CY1379A (da)
DE (1) DE3248160C2 (da)
DK (1) DK162389C (da)
ES (2) ES518510A0 (da)
FI (1) FI70891C (da)
FR (1) FR2518993B1 (da)
GB (1) GB2114122B (da)
GR (1) GR77045B (da)
HK (1) HK5288A (da)
IE (1) IE54619B1 (da)
IT (1) IT1158039B (da)
KE (1) KE3709A (da)
LU (1) LU84561A1 (da)
NL (1) NL193283C (da)
PT (1) PT76036B (da)
SE (1) SE453088B (da)
SG (1) SG29787G (da)
ZA (1) ZA828549B (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4581357A (en) * 1983-02-07 1986-04-08 Mead Johnson & Company Antipsychotic 5-fluoro-pyrimidin-2-yl piperazine compound
US5187276A (en) * 1983-06-18 1993-02-16 Troponwerke Gmbh & Co. Kg. 2-pyrimidinyl-1-piperazine derivatives
DE3321969A1 (de) * 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-pyrimidinyl-1-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4668687A (en) * 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
CA1250291A (en) * 1984-07-23 1989-02-21 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)-piperazinyl derivatives of 1-pyrrolidin-2-ones
HUT43600A (en) * 1985-06-22 1987-11-30 Sandoz Ag Process for production of new thiazole derivatives and medical compound containing those
NZ216720A (en) * 1985-07-08 1990-09-26 Bristol Myers Co Diazinylpiperidine derivatives and pharmaceutical compositions
US4826843A (en) * 1985-07-08 1989-05-02 Bristol-Myers Cerebral function enhancing diazinylpiperidine derivatives
US4777254A (en) * 1986-12-02 1988-10-11 American Home Products Corp. Cyclic imides as H1 -antagonists
US4771053A (en) * 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US4782060A (en) * 1987-07-29 1988-11-01 Bristol-Myers Company Gepirone for alleviation of panic disorders
US4880930A (en) * 1987-11-30 1989-11-14 New James S Psychotropic acyclic amide derivatives
US5001130A (en) * 1988-02-18 1991-03-19 Bristol-Myers Company Psychotropic heterobicycloalkylpiperazine derivatives
US5116970A (en) * 1988-02-18 1992-05-26 New James S Psychotropic heterobicycloalkylpiperazine derivatives: 2. fused pyridazinones
US4780466A (en) * 1988-03-17 1988-10-25 Hoechst-Roussel Pharmaceuticals, Inc. Arylpiperazinylalkoxy derivatives of cyclic imides
US5242911A (en) * 1988-06-17 1993-09-07 Pfizer Inc. Bridged bicyclic imides as anxiolytics and antidepressants
WO1990002552A1 (en) * 1988-09-16 1990-03-22 Pfizer Inc. Antipsychotic 4-[4-(3-benzisothiazolyl)-1-piperazinyl]butyl bridged bicyclic imides
FR2654934B1 (fr) * 1989-11-29 1994-09-30 Midy Spa Utilisation de derive [4-(2-pyrimidinyl)-1-piperazinyl] butyliques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale.
US5098904A (en) * 1990-06-27 1992-03-24 Bristol-Myers Squibb Company Cerebral function enhancing pyrimidinyl derivatives
AU9164591A (en) * 1990-12-14 1992-07-08 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DE4135551A1 (de) * 1991-08-31 1993-03-04 Schering Ag Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
US5824680A (en) * 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
GB9223153D0 (en) * 1992-11-05 1992-12-16 Wyeth John & Brother Ltd Piperazine derivatives
FR2701260B1 (fr) * 1993-02-05 1995-05-05 Esteve Labor Dr Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments.
US5338738A (en) * 1993-04-19 1994-08-16 Bristol-Myers Squibb Company Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines
FR2705098B1 (fr) * 1993-05-10 1995-08-04 Esteve Labor Dr Procédé de préparation de 2-{4-[4-(chloro-1-pyrazolyl)butyl]1-pipérazinyl}pyrimidine (Lesopitron) .
US5538985A (en) * 1994-01-27 1996-07-23 Mitsui Toatsu Chemicals, Inc. Pyrrolidinone derivatives
CA2146593A1 (en) * 1994-05-05 1995-11-06 Jack Melton Large-scale process for azapirone synthesis
US5521313A (en) * 1994-05-05 1996-05-28 Bristol-Myers Squibb Company Process for preparing certain azapirones
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
WO2000006163A1 (en) * 1998-07-30 2000-02-10 Bristol-Myers Squibb Company Improved method for treatment of sleep-related respiratory disorders
US6566361B2 (en) 1999-06-30 2003-05-20 Laboratories, Upsa Azapirone pain treatment
CN100367965C (zh) * 1999-12-20 2008-02-13 法布瑞－克雷默制药有限公司 吉吡隆代谢物在制备改善哺乳动物不良心理状态的组合物上的应用
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
HUP0204050A3 (en) * 2000-01-19 2004-09-28 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
AU2001295478A1 (en) * 2000-08-22 2002-03-04 Akzo Nobel N.V. Active metabolite of gepirone
EP1341777B1 (en) * 2000-11-29 2007-09-26 Eli Lilly And Company 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatement of incontinence
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
ATE532772T1 (de) * 2003-07-30 2011-11-15 Xenon Pharmaceuticals Inc Piperazinderivate und deren verwendung als therapeutische mittel
ES2347152T3 (es) * 2003-11-26 2010-10-26 Pfizer Products Inc. Derivados de aminopirazol como inhibidores de gsk-3.
US20060099267A1 (en) * 2004-11-05 2006-05-11 Fabre-Kramer Pharmaceuticals, Inc. High-dosage extended-release formulation of gepirone
MX2007005368A (es) * 2004-11-05 2007-09-11 Fabre Kramer Holdings Inc Formulacion con liberacion prolongada de dosis alta de gepirona.
EA017351B1 (ru) * 2007-03-29 2012-11-30 Общество С Ограниченной Ответственностью "Фармвинг" Средство противогистаминного антиаллергического действия и способ его получения
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
IT201900000657A1 (it) 2019-01-16 2020-07-16 Procos Spa Processo per la sintesi di gepirone
GB202014736D0 (en) * 2020-09-18 2020-11-04 Imperial College Innovations Ltd Novel compounds and their use in therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3398151A (en) * 1966-02-01 1968-08-20 Mead Johnson & Co Azaspirodecanediones and azaspiroundecanediones
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
DK251079A (da) 1978-06-20 1979-12-21 Synthelabo Fremgangsmaade til fremstilling af phenylpiperazinderivater
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines

Also Published As

Publication number Publication date
NL193283C (nl) 1999-05-06
SE8207425D0 (sv) 1982-12-27
CA1244426A (en) 1988-11-08
JPH0368875B2 (da) 1991-10-30
FI824442L (fi) 1983-06-29
SG29787G (en) 1987-07-17
ES8405786A1 (es) 1984-06-16
SE453088B (sv) 1988-01-11
LU84561A1 (fr) 1983-09-08
JPS58118582A (ja) 1983-07-14
IE54619B1 (en) 1989-12-20
FI70891B (fi) 1986-07-18
ATA469882A (de) 1986-07-15
CY1379A (en) 1987-08-07
AU555797B2 (en) 1986-10-09
CH656383A5 (de) 1986-06-30
KE3709A (en) 1987-04-16
DE3248160A1 (de) 1983-07-07
PT76036A (en) 1983-01-01
GB2114122A (en) 1983-08-17
IT1158039B (it) 1987-02-18
HK5288A (en) 1988-01-29
KR840002827A (ko) 1984-07-21
SE8207425L (sv) 1983-08-12
NL193283B (nl) 1999-01-04
AU9108382A (en) 1983-07-07
NL8204970A (nl) 1983-07-18
FI824442A0 (fi) 1982-12-23
DK162389B (da) 1991-10-21
ZA828549B (en) 1983-09-28
GB2114122B (en) 1985-11-27
FR2518993B1 (fr) 1986-09-05
DK162389C (da) 1992-03-09
PT76036B (en) 1985-12-16
AT382373B (de) 1987-02-25
ES524945A0 (es) 1985-08-01
FR2518993A1 (fr) 1983-07-01
FI70891C (fi) 1986-10-27
KR870001045B1 (ko) 1987-05-26
IT8249719A0 (it) 1982-12-22
US4423049A (en) 1983-12-27
ES518510A0 (es) 1984-06-16
DE3248160C2 (de) 1993-12-09
ES8506696A1 (es) 1985-08-01
GR77045B (da) 1984-09-04
IE823067L (en) 1983-06-28
JPH06293753A (ja) 1994-10-21
BE895504A (fr) 1983-06-28

Similar Documents

Publication Publication Date Title
DK573182A (da) Fremgangsmaade til fremstilling af 2-(4-((4,4-dialkyl-2,6-piperidindion-1-yl)butyl)-1-piperasinyl)pyrimidiner
DK307590D0 (da) Analogifremgangsmaade til fremstilling af 8-(4-(4-(2,1-benzisothiazol-3-yl)-1-piperazinyl)butyl)-8-azaspiro(4.5)decan-7,9-dion
DK159442C (da) Analogifremgangsmaade til fremstilling af 6,7-substitueret-4-ethyl-quinazoliner
DK573282A (da) Fremgangsmaade til fremstilling af 2-(4-((4,4-dialkyl-2,6-piperidindion-1-yl)-butyl)-1-piperazinyl)pyridiner
DK143491A (da) Fremgangsmaade til fremstilling af 3-oen-phenylacetylaminopiperidinaa-2,6-dion
DK161147C (da) Analogifremgangsmaade til fremstilling af oe3haa-imidazo-oe5,1-daa-1,2,3,5-tetrazin-4-onderivater
DK379985D0 (da) Fremgangsmaade til fremstilling af 6-chlor-n-methyl-2,3,4,5-tetrahydro-lh-benzazepin
DK155281C (da) Fremgangsmaade til fremstilling af 1,2-dihydro-6-methyl-2-oxo-5-(pyridinyl)nicotinonitriler
DK152428C (da) Analogifremgangsmaade til fremstilling af 2-(aminoalkylthio)-quinolinderivater
DK157855C (da) Fremgangsmaade til fremstilling af 2,3-dichlor-5-trichlormethylpyridin
DK40482A (da) Fremgangsmaade til fremstilling af 2-(2-(1,4-benzodioxanyl))-2-imidazolinderivater
DK314682A (da) Fremgangsmaade til fremstilling af substituerede thiazolo-(3,2-a)pyrimidiner
DK113483A (da) Fremgangsmaade til fremstilling af 3,4-diphenyl-5-methylpyrazolderivater
DK153488C (da) Fremgangsmaade til fremstilling af 5,6,7,7a-tetrahydro-4h-thieno(3,2-c-)-pyridin-2-onderivater
DK97682A (da) Fremgangsmaade til fremstilling af 1-(1,3-benzodioxol-5-yl)-2-pyrrolidinon
DK79982A (da) Fremgangsmaade til fremstilling af 3-(4-phenyl-1-piperazinio-1-yl)-1,2-propandiol-3-(theophyllin-7-yl)-1-propan-sulfonat
DK513580A (da) Fremgangsmaade til fremstilling af 4,5-diaryl-alfa (polyhalogenalkyl)-1h-imidazol-2-methanoler
DK5782A (da) Fremgangsmaade til fremstilling af 3-picolin
DK214479A (da) Fremgangsmaade til fremstilling af 2,4-diamono-5-(3,5-dialkyl-4-hydroxybenzyl) pyrimidiner
DK157999C (da) Fremgangsmaade til fremstilling af 5,11-dihydro-6h-pyridooe2,3-baaoe1,4aabenzodiazepin-6-oner
DK152730C (da) Fremgangsmaade til fremstilling af 8-ae4-oe4-(2-pyrimidinyl)-1-piperazinylaa-butylaa-8-azaspiro(4,5)-dekan-7,9-dion
DK155434C (da) Fremgangsmaade til fremstilling af 2,4-diamino-5-(3',4',5'-trimethoxybenzyl)pyrimidin
DK522982A (da) Fremgangsmaade til fremstilling af 8-halogenalkyl-4h-(1)-benzopyran-4-on-forbindelser
DK527182A (da) Fremgangsmaade til fremstilling af n,n-dialkyl-alfa-(3-pyridyl)-m-dioxan-5-methylaminer
DK153402C (da) Analogifremgangsmaade til fremstilling af 3-(2-methoxy-phenoxy)-3-methyl-benzo-2,4-dioxacyklohexanon

Legal Events

Date Code Title Description
PUP Patent expired